With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110-70-3,N1,N2-Dimethylethane-1,2-diamine,as a common compound, the synthetic route is as follows.
Preparation of Methyl-(2-methylamino-ethyl)-carbamic acid tert-butyl esterTo an ice-cooled solution of N,N’-dimethyethylenediamine (10 ml_, 91.0 mmol) in dry THF (150 ml.) was added a solution of BoC2O (4.97 g, 22.8 mmol) in dry THF (50 ml.) over 30 minutes. The reaction mixture was stirred for 1 h at 00C then at rt overnight, and concentrated in vacuo. The resulting residue was taken up in a mixture of EA and a sat.NH4CI solution. The organic layer was separated, washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure. FC (10 % MeOH in DCM) afforded the title compound as a yellow oil (2.90 g, 17%). LC-MS (analytic A, Zorbax SB-AQ column, acidic conditions): tR = 0.50 min; [M+H]+ 189.40.
The synthetic route of 110-70-3 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; ACTELION PHARMACEUTICALS LTD; AISSAOUI, Hamed; BOSS, Christoph; CORMINBOEUF, Olivier; FRANTZ, Marie-Celine; GRISOSTOMI, Corinna; WO2010/58353; (2010); A1;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis